RT Journal Article
T1 Perioperative chemotherapy versus surgery alone for resectable colorectal liver metastases: an international multicentre propensity score matched analysis on long-term outcomes according to established prognostic risk scores.
A1 Di Martino, Marcello
A1 Primavesi, Florian
A1 Syn, Nicholas
A1 Dorcaratto, Dimitri
A1 de la Hoz Rodríguez, Ángela
A1 Dupré, Aurélien
A1 Piardi, Tullio
A1 Rhaiem, Rami
A1 Blanco Fernández, Gerardo
A1 Prada Villaverde, Arancha
A1 Rodríguez Sanjuán, Juan C
A1 Fernández Santiago, Roberto
A1 Fernández-Moreno, María-Carmen
A1 Ferret, Georgina
A1 López Ben, Santiago
A1 Suárez Muñoz, Miguel Á
A1 Perez-Alonso, Alejandro J
A1 Koh, Ye-Xin
A1 Jones, Robert
A1 Martín-Pérez, Elena
AB There is still uncertainty regarding the role of perioperative chemotherapy (CTx) in patients with resectable colorectal liver metastases (CRLM), especially in those with a low-risk of recurrence. Multicentre retrospective analysis of patients with CRLM undergoing liver resection between 2010-2015. Patients were divided into two groups according to whether they received perioperative CTx or not and were compared using propensity score matching (PSM) analysis. Then, they were stratified according to prognostic risk scores, including: Clinical Risk Score (CRS), Tumour Burden Score (TBS) and Genetic And Morphological Evaluation (GAME) score. The study included 967 patients with a median follow-up of 68 months. After PSM analysis, patients with perioperative CTx presented prolonged overall survival (OS) in comparison with the surgery alone group (82.8 vs 52.5 months, p = 0.017). On multivariable analysis perioperative CTx was an independent predictor of increased OS (HR 0.705, 95%CI 0.705-0.516, p = 0.029). The benefits of perioperative CTx on survival were confirmed in patients with CRS and TBS scores ≤2 (p = 0.022 and p = 0.020, respectively) and in patients with a GAME score ≤1 (p = 0.006). Perioperative CTx demonstrated an increase in OS in patients with CRLM. Patients with a low-risk of recurrence seem to benefit from systemic treatment.
YR 2021
FD 2021-05-15
LK https://hdl.handle.net/10668/26482
UL https://hdl.handle.net/10668/26482
LA en
DS RISalud
RD Apr 12, 2025